Baird Financial Group Inc. Acquires 1,319 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Baird Financial Group Inc. lifted its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 2.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 61,023 shares of the medical research company’s stock after buying an additional 1,319 shares during the quarter. Baird Financial Group Inc.’s holdings in IQVIA were worth $11,992,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Tidal Investments LLC increased its holdings in shares of IQVIA by 9.3% in the third quarter. Tidal Investments LLC now owns 5,980 shares of the medical research company’s stock valued at $1,417,000 after purchasing an additional 509 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of IQVIA by 0.8% in the 3rd quarter. Principal Financial Group Inc. now owns 209,021 shares of the medical research company’s stock valued at $49,532,000 after buying an additional 1,750 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares during the period. GAMMA Investing LLC boosted its holdings in IQVIA by 27.7% in the fourth quarter. GAMMA Investing LLC now owns 1,406 shares of the medical research company’s stock valued at $276,000 after acquiring an additional 305 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its position in IQVIA by 1.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock worth $1,068,000 after purchasing an additional 56 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on IQV. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 target price on shares of IQVIA in a report on Monday, February 10th. JPMorgan Chase & Co. reduced their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. Morgan Stanley upped their price target on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research note on Tuesday, February 11th. Mizuho lowered their target price on shares of IQVIA from $242.00 to $210.00 and set an “outperform” rating for the company in a research note on Wednesday, April 9th. Finally, Barclays decreased their price target on shares of IQVIA from $170.00 to $165.00 and set an “equal weight” rating for the company in a report on Wednesday. Eight research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus price target of $231.71.

IQVIA Stock Up 4.8 %

Shares of IQV stock opened at $153.21 on Thursday. The firm has a market capitalization of $27.01 billion, a P/E ratio of 20.43, a PEG ratio of 1.99 and a beta of 1.34. The firm’s fifty day moving average price is $165.23 and its two-hundred day moving average price is $189.61. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1 year low of $135.97 and a 1 year high of $252.88.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. The firm had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The company’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.54 earnings per share. On average, equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.